PROBIOTYKI A ZDROWIE - DZIŚ I JUTRO

Dominika Winiarz, Kamila Domańska, Kinga Paluch, Dorota Skrajnowska

Bibliografia

1.    Mojka K. Probiotyki, prebiotyki i synbiotyki - charakterystyka i funkcje. Probiotyki, prebiotyki i synbiotyki. Prob. Hig. Epidemiol. 2014, 95(3), 541-549.

2.    FAO/WHO: Guidelines for the Evaluation of Probiotics in Food. Report of a Joint FAO/WHO Working Group on Drafting Guidelines for the Evaluation of Probiotics in Food. London, Onatario,Kanada, 30 kwietnia - 1 maja 2002.

3.    Wyszyńska A, Kobierecka P, Jagusztyn-Krynicka E K. Bakterie kwasu mlekowego (lab) jako wektory do konstrukcji szczepionek. Post. Mikrobiol. 2015, 54, (2), 141-153.

4.    Lutyńska A, Augustynowicz E, Wiatrzyk A. Problemy stosowania suplementów diety zawierających probiotyki. Prob.. Hig. Epidemiol. 2012, 93(3), 493-498.

5.    Nowak A, Śliżewska K, Libudzisz Z. Probiotyki - historia i mechanizmy działania. Żywność. Nauka. Technologia. Jakość. 2010, 4, 5-19.

6.    Szajewska H. Probiotyki w Polsce - kiedy, jakie i dlaczego? Gastroenterologia Kliniczna. 2010, 2(1), 1-9.

7.    Jach M, Łoś R, Maj M, Malm A. Probiotyki - aspekty funkcjonalne i technologiczne. Post. Mikrobiol. 2013, 52(2) 161-170.

8.    Health and Nutritional Properties of Probiotics in Food including Powder Milk with Live Lactic Acid Bacteria. Report of a'Joint FAO/WHO Export Consultation, Cordoba, Argentina, 1-4.10.2001.

9.    Forrsten SD, Sindelar CW, Ouwehand AC. Probiotics from an industrial perspective. Anaerobe. 2011, 17, 410-413.

10.  Chen S, Zhao Q, Ferguson LR, Shu Q, Weir I, Garg S. Development of a novel probiotic delivery system based on microencapsulation with protectans. Appl. Microbiol. Biotechnol. 2012, 93, 1447-1457.

11.  Burgain J, Gaiani C, Linder M, Scher J. Encapsulation of probiotic living cells: From laboratory scale to industrial applications. J. Food. Engineering. 2011, 104, 467-483.

12.  Libudzisz Z. Probiotics and prebiotics in fermented milks. Ped. Wsp. 2002, 4, 19-25.

13.  Ewaschuck JB, Madsen KL. Mechanisms of probiotic effects: a review. Functional Food Rev. 2009, 1, 29-41.

14.  Oelschalaeger TA. Mechanisms of probiotic action - A review. Int. J. Med. Microbiol. 2010, 300, 57-62.

15.  Collado MC, Meriluoto J, Salminem S. Adhesion and aggregation properties of probiotic and pathogen strains. Eur. Food Res. Technol. 2008, 226, 1065-1073.

16.  Collado MC, Meriluoto J, Salminem S. In vitro analysis of probiotic strain combinations to inhibit pathogen adhesion to human intestinal mucus. Food Res. Int. 2007, 40, 629-639.

17.  Stolarczyk A, Socha P, Socha J. Probiotics and prebiotics in prophylactic and therapeutic use in children. Terapia, 2002, 1, 116.

18.  Grajek W, Sip A. Antagonistic activity of probiotics against pathogenic microorganisms. Zakazenia. 2006, 1, 49-54.

19.  Lin SC, Lo YC, Wu H. Helical assembly in the MyD88-IRAK4-IRAK2 complex in TLR/IL-1R signaling. Nature. 2010, 465, 885-890.

20.  Shandilya UKr, Jadhav S, Panwar V, Kansal VK. Probiotics: Potent Immunomodulatory Tool Against Allergy. Probiotics & Antimicro. Prot. 2011, 3, 151-158.

21.  Jijon H, Backer J, Diaz H, Yeung H, Thiel D, McKaigney C, De Simone C, Madsen K. DNA from probiotic bacteria modulates murine and human epithelial and immune function. Gastroenterology. 2004, 126, 1358-1373.

22.  Matsumoto S, Hara T, Hori T, Mitsuyama K, Nagaoka M, Tomiyasu N, Suzuki A, Sata M. Probiotic Lactobacillus-induced improvement in murine chronic inflammatory bowel disease is associated with the down-regulation of pro-inflammatory cytokines in lamina propria mononuclear cells. Clin. Exp. Immunol. 2005, 140, 417-426.

23.  Zeuthen LH, Fink LN, Frokiaer H. Epithelial cells prime the immune response to an array of gutderived commensals towards a tolerogenic phenotype through distinct actions of thymic stromal lymphopoietin and transforming growth factor-beta. Immunology. 2008, 123, 197-208.

24.  Shida K, Nanno M. Probiotics and immunology: separating the wheat from the chaff. Trends Immunol. 2008, 29, 565-573.

25.  de Vos WM. Systems solutions by lactic acid bacteria: from paradigms to practice. Microb. Cell Fact.,10 Suppl 1, S2. 2011, doi: 10.1186/1475-2859-10-S1-S2.

26.  Aggarwal J, Swami G, Kumar M. Probiotics and their Effects on Metabolic Diseases: An Update. J. Clin. Diagn. Res. 2013, 7, 173-177.

27.  Socha P, Stolarczyk M, Socha J. Wpływ probiotyków i prebiotyków na gospodarkę lipidową. Pediatr Współcz Gastroenterol Hepat Żyw Dziecka 2002, 04, 85-88.

28.  Wickens K, Black PN, Stanley TV. Mitchell E, Fitzharris P, Tannock GW, Purdie G, Crane J. A differential effect of 2 probiotics in the prevention of eczema and atopy: a double-blind, randomized, placebo-controlled trial. J. Allergy Clin. Immunol. 2008, 122(4), 788-94.

29.  Kukowska A, Dziadziuszko R, Jassem J. Metody losowego przydziału leczenia w badaniach klinicznych. Onkologia w Praktyce Klinicznej. 2005, 1(3), 151-156.

30.  Bartlett JG. Antibiotic-associated diarrhoea. N. Engl. J. Med. 2002, 346, 334-339.

31.  Szajewska H, Ruszczyński M, Radzikowski A. Probiotics in the prevention of antibiotic-associated diarrhea in children: a meta-analysis of randomized controlled trials. J. Pediatr. 2006, 149, 367-372.

32.  Szajewska H, Mrukowicz J. Meta-analysis: non-pathogenic yeast Saccharomyces boulardii in the prevention of antibiotic- associated diarrhea. Aliment. Pharmacol. Ther. 2005, 22, 365-372.

33.  Hawrelak JA, Whitten DL, Myers SP. Is Lactobacillus rhamnosus GG effective in preventing the onset of antibioticassociated diarrhoea: a systematic review. Digestion. 2005, 72, 51-56.

34.  Guarino A, Albano F, Ashkenazi S. Gendrel D, Hoekstra JH, Shamir R, Szajewska H. European Society for Paediatric Gastroenterology, Hepatology and Nutrition/ /European Society for Paediatric Infectious Diseases Evidence–based Guidelines for the Management of Acute Gastroenteritis in children in Europe: Executive summary. J. Pediatr. Gastroenterol. Nutr. 2008, 46, 619-621.

35.  Van Niel C, Feudtner C, Garrison MM, Christakis DA. Lactobacillus therapy for acute infectious diarrhea in children: a metaanalysis. Pediatrics. 2002, 109, 678-684.

36.  Huang JS, Bousvaros A, Lee JW, Diaz A, Davidson EJ. Efficacy of probiotic use in acute diarrhea in children: a meta-analysis. Dig. Dis. Sci. 2002, 47, 2625-2634.

37.  Szajewska H, Skórka A, Ruszczyński M. Gieruszczak-Białek D. Meta-analysis: Lactobacillus GG for treating acute diarrhoea in children. Aliment. Pharmacol. Ther. 2007, 25, 871-881.

38.  Szajewska H, Skórka A. Saccharomyces boulardii for treating acute gastroenteritis in children: updated meta-analysis of randomized controlled trials. Aliment. Pharmacol. Ther. 2009, 30, 960-961.

39.  McFarland LV. Meta-analysis of probiotics for the prevention of antibiotic associated diarrhea and the treatment of Clostridium difficile disease. Am. J. Gastroenterol. 2006, 101, 812-822.

40.  Dendukuri N, Costa V, McGregor M, Brophy JM. Probiotic therapy for the prevention and treatment of Clostridium difficileassociated diarrhea: a systematic review. CMAJ. 2005, 173, 167-170.

41.  D’Souza AL, Rajkumar C, Cooke J, Bulpitt Ch. Probiotics in prevention of antibiotic associated diarrhoea: Meta-analysis. BMJ. 2002, 324,1361.

42.  McFarland L.V., Dublin S. Meta-analysis of probiotics for the treatment of irritable bowel syndrome. World J. Gastroenterol. 2008, 14, 2650-2656.

43.  Dendukuri N, Brophy J. Inappropriate use of meta-analysis to estimate efficacy of probiotics. Am. J. Gastroenterol. 2007, 102 (1), 201.

44.  Tong JL., Ran ZH, Shen J, Zhang CX, Xiao SD. Meta-analysis: the effect of supplementation with probiotics on eradication rates and adverse events during Helicobacter pylori eradication therapy. Aliment. Pharmacol. Ther. 2007, 25, 155-168.

45.  Moayyedi P., Ford A.C., Talley N.J. Cremonini F., Foxx-Orenstein A.E., Brandt L.J., Quigley E.M. The efficacy of probiotics in the therapy of irritable bowel syndrome: a systematic review. 2010, 59(3), 325-332.

46.  Hoveyda N., Heneghan C., Mahtani K.R., Perera R., Roberts N., Glasziou P. A systematic review and meta-analysis: probiotics in the treatment of irritable bowel syndrome. BMC Gastroenterol. 2009, 9, 15.

47.  Huertas-Ceballos A., Logan S., Bennett C., Macarthur C. Psychosocial interventions for recurrent abdominal pain (RAP) and irritable bowel syndrome (IBS) in childhood. Cochrane Database of Systematic Reviews. 2008, 1, CD003014.

48.  Chmielewska A, Szajewska H. Systematic review of randomised controlled trias: probiotics for functional constipation. World J. Gastroenterol. 2010, 16, 69-75.

49.  Butterworth AD, Thomas AG, Akobeng AK. Probiotics for induction of remission in Crohn’s disease. Cochrane Database of Systematic Reviews. 2008, Issue 3. Art. No.: CD006634. DOI: 10.1002/14651858.CD006634.pub2.

50.  Rahimi R, Nikfar S, Rahimi F., Elahi B., Derakhshani S., Vafaie M., Abdollahi M. A meta-analysis on the efficacy of probiotics for maintenance of remission and prevention of clinical and endoscopic relapse in Crohn’s disease. Dig. Dis. Sci. 2008, 53, 2524-2531.

51.  Lherm T, Monet C, Nougiere B, Soulier M, Larbi D, Le Gall C, Caen D, Malbrunot C. Seven cases of fungemia with Saccharomyces boulardii in critically ill patients. Intensive Care Med 2002, 28,797-801.

52.  Braat H, de Jong EC, van den Brande JM, Kapsenberg ML, Peppelenbosch MP, van Tol EA, van Deventer SJ. Dichotomy between Lactobacillus rhamnosus and Klebsiella pneumoniae on dendritic cell phenotype and function. J Mol Med. 2004, 82,197-205.

53.  Zocco M.A., dal Verme L.Z., Cremonini F., Piscaglia A.C.,Nista E.C., Candelli M., Novi M., Rigante D., Cazzato I.A., Ojetti V., Armuzzi A, Gasbarrini G, Gasbarrini A.: Efficacy of Lactobacillus GG in maintaining remission of ulcerative colitis. Aliment. Pharmacol. Ther. 2006, 23, 1567-1574.

54.  Boyle R.J., Robins-Browne R.M., Tang M.L.K. Probiotic use in clinical practice: what are the risks? Am. J. Clin. Nutr. 2006, 83, 1256-1264.

55.  Sun S., Yang K., He X., Tian J., Ma B., Jiang L. Probiotics in patients with severe acute pancreatitis: a meta-analysis. Langenbecks Arch. Surg. 2009, 394, 171-177.

56.  Morrow LE, Kollef MH, Casale TB. Probiotic prophylaxis of ventilator-assosiated pneumonia- a blinded, randomized, controlled trial. Am J Respir Crit Care Med. 2010, 182,1058-1064.

57.  Aceti A, Gori D, Barone G, Callegari ML, Di Mauro A, Fantini MP, Indrio F, Maggio L, Meneghin F, Morelli L, Zuccotti G, Corvaglia L and on behalf of the Italian Society of Neonatology Probiotics for prevention of necrotizing enterocolitis in preterm infants: systematic review and meta-analysis Italian J of Pediatrics. 2015, 41,89.

58.  Lolis N, Veldekis D, Moraitou H, Kanavaki S, Velegraki A, Triandafyllidis C, Tasioudis C, Pefanis A, Pneumatikos I. Saccharomyces boulardii fungaemia in an intensive care unit patient treated with caspofungin. Crit Care. 2008, 12, 414.

59.  Santino I, Alari A, Bono S, Teti E, Marangi M, Bernardini A, Magrini L, Di Somma S, Teggi A. Saccharomyces cerevisiae fungemia, a possible consequence of the treatment of Clostridium difficile colitis with a probioticum. Int J Immunopathol Pharmacol. 2014, 27,143-146.

60.  Vahabnezhad E, Mochon AB, Wozniak LJ, Ziring DA Lactobacillus bacteremia associated with probiotic use in a pediatric patient with ulcerative colitis. J Clin Gastroenterol. 2013, 47, 437-439.

61.  Conen A, Zimmerer S, Frei R, Trampuz A, Battegay M, Elzi L. A pain in the neck: probiotics for ulcerative colitis. Ann Intern Med. 2009, 151, 895-897.

62.  Ku W. Probiotics provoked D-lactic acidosis in short bowel syndrome: case report and literature review. HK J Paediatr. 2006, 11, 246-254.

63.  Besselink MG, van Santvoort HC, Buskens E, Boermeester MA, van Goor H, Timmerman HM, Nieuwenhuijs VB, Bollen TL, van Ramshorst B, Witteman BJ, Rosman C, Ploeg RJ, Brink MA, Schaapherder AF, Dejong CH, Wahab PJ, van Laarhoven CJ, van der Harst E, van Eijck CH, Cuesta MA, Akkermans LM, Gooszen HG; Dutch Acute Pancreatitis Study Group. Probiotic prophylaxis in predicted severe acute pancreatitis: a randomised, double-blind, placebo-controlled trial. Lancet. 2008, 371,651-659.

64.  Vaarala O. Immunological effects of probiotics with special reference to lactobacilli. Clin Exp Allergy. 2003, 33,1634-1640.

65.  Drakes M, Blanchard T, Czinn S Bacterial probiotic modulation of dendritic cells. Infect Immun. 2004, 72, 3299-3309.

66.  Marteau P.R. Probiotics in clinical conditions. Clin. Rev. Allergy Immunol. 2002, 22, 255-273.

67.  Cannon J.P., Lee T.A., Bolanos J.T., Danziger L.H.: Pathogenic relevance of Lactobacillus: a retrospective review of over 200 cases. Eur. J. Clin. Microbiol. Infect. Dis. 2005, 24, 31-40.

68.  Kubiszewska I, Januszewska M, Rybka J, Gackowska L. Bakterie kwasu mlekowego i zdrowie: czy probiotyki są bezpieczne dla człowieka? Postepy Hig Med Dosw (online). 2014, 68, 1325-1334.

69.  Floch M.H., Walker W.A., Guandalini S., Hibberd P., Gorbach S., Surawicz C., Sanders M.E., Garcia-Tsao G., Quigley E.M., Isolauri E., Fedorak R.N., Dieleman L.A. Recommendations for probiotic use - J. Clin. Gastroenterol. 2008, 42 (supl. 2), S104-108.

70.  Fric P. Probiotics and prebiotics - renaissance of a therapeutic principle. CEJ Med. 2007, 2, 237-270.

71.  Kligler B., Hanaway P., Cohrssen A. Probiotics in children. Pediatr. Clin. North Am. 2007, 54, 949-967.

72.  Libudzisz Z.: Human intestinal microflora and probiotics. Zakażenia, 2004, 6, 47-51.

73.  Shanahan F.: Probiotics in perspective. Gastroenterology, 2010, 139, 1808-1812.

74.  Sleator R.D., Hill C.: New frontiers in probiotic research. Lett. Appl. Microbiol. 2008, 46, 143-147.

75.  Szewczyk, K., Wzrost Listeria monocytogenes a warunki środowiskowe, Przemysł spożywczy 11/2015 (69), 12-15.

76.  Sheehan V.M., Sleator R.D., Fitzgerald G.F., Hill C.: Heterologous expression of BetL, a betaine uptake system, enhances the stress tolerance of Lactobacillus salivarius UCC118. Appl. Environ. Microbiol. 2006, 72, 2170.

77.  Corcoran BM, Ross RP, Fitzgerald GF, Dockery P, Santon C. Enhanced survival of GroESL-overproducing Lactobacillus paracasei NFBC 338 under stressful conditions induced by drying. Appl. Environ. Microb. 2006, 72, 5104-5107.

78.   Paton A.W., Morona R., Paton J.C.: Receptor-mimic probiotics: potential therapeutics for bacterial toxin-mediated enteric diseases. Expert Rev. Gastroenterol. Hepatol. 2010, 4, 253-255.

79.  Guimarães V.D., Gabriel J.E., Lefèvre F., Cabanes D., Gruss'A., Cossart P.: Internalin-expressing Lactococcus lactis is able to invade small intestine of guinea pigs and deliver DNA into mammalian epithelial cells. Microbes Infect. 2005, 7, 836-44.

80.   Toczek K, Glibowski P. Bakterie probiotyczne w żywności nowe kierunki stosowania. Przemysł Spożywczy. 2015, 69, 42-45.

81.  Osęka G. Oświadczenia zdrowotne dotyczące probiotyków. Przemysł Spożywczy. 2014, 68(12), 28-29.

82.  Bulwarska M., Florowska A.: Lody z dodatkami prozdrowotnymi. Przemysł spożywczy. 2011, 65, 11, 22-24.

83.  Szydłowska A., Kołożyn-Krajewska D. Zastosowanie bakterii potencjalnie probiotycznych do fermentacji przecieru z dyni. Żywność. Nauka. Technologia. Jakość. 2010, 73, 6, 109 -119.

84.  Trząskowska M. Probiotyki w produktach pochodzenia roślinnego. Żywność. Nauka.Technologia. Jakość. 2013, 89, 4, 5-20.

85.  Arihara K. Strategies for designing novel functional meat products. Meat Science. 2006 74, 1, 219-229.

86.  Altamirano-Fortoul R., Moreno-Terrazas R., Quezada-Gallo A., Rosell C.: Viability ofsome probioticcoatings in bread and its effect on the crust mechanical properties. Food Hydrocolloids. 2012, 1, 29, 166-174.

87.  Steinka I. Wybrane aspekty stosowania probiotyków. Ann. Acad. Med. Gedan. 2011, 41, 97-108.

88.  Zielińska D, Ołdak A, Rzepkowska A, Kołożyn-Krajewska D. Metody identyfikacji probiotyków w żywności. Wyzwania i problemy. Przemysł Spożywczy. 2017, 1, 71.

89.  Guidance on the scientific requirements for health claims related to the immune system, the gastrointestinal tract and defence against pathogenic microorganisms EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) PUBLISHED: 18 January 2016 doi:10.2903/j.efsa.2016.4369.